Breaking News

Pfizer-BioNTech Upgrades Deliveries

Laboratories will increase arrivals to EU countries by 50 million doses, Ursula von der Leyen announced on Wednesday. A decision that comes after the decision to delay the deployment of bottles from the American laboratory Johnson & Johnson.

Laboratories will increase arrivals to EU countries by 50 million doses, Ursula von der Leyen announced on Wednesday. A decision that comes after the decision to delay the deployment of bottles from the American laboratory Johnson & Johnson.

(ASdN with AFP) – The vaccination campaign is accelerating in Europe. 24 hours after the brake on Johnson & Johnson, the President of the European Commission Ursula von der Leyen announced on Wednesday that 50 million additional doses of the Pfizer vaccine were expected “from April”.

While new deliveries should therefore arrive in the coming days, Brussels also intends to develop its longer-term strategy. The Commission has thus opened “formal negotiations” with BioNTech and Pfizer, the chief executive told the press. The objective: to order 1.8 billion additional doses of so-called “2nd generation” vaccines, intended to fight against current and future variants of the coronavirus.

These vaccines, whose deliveries are scheduled for 2022 and 2023, will be added to the 2.6 billion doses already ordered by the EU and which must be delivered to the 27 this year and next year.

The objective is to anticipate the mass vaccination of children and adolescents, but above all the emergence of variants against which the vaccines currently administered could prove to be powerless – which would require formulas modified accordingly.

The messenger RNA technology, used by BioNTech-Pfizer but also by the American Moderna, is considered to be faster and easier to adapt, and messenger RNA vaccines are currently considered to be more effective against the so-called “southern” variants. African ”and“ Brazilian ”. Unlike the AstraZeneca.

While Europeans have faced significant delays in laboratory delivery, this new contract will provide for a “delivery obligation” with a monthly – and no longer quarterly – schedule for deliveries, according to a European source.

In addition, the production of vaccines but also of their components will have to be based in Europe, urged Ursula von der Leyen on Wednesday. She said she hoped that the negotiations “will be concluded very quickly”, without ruling out that “other contracts with other groups” may follow.

The European Commission – in charge of vaccine pre-orders on behalf of the Member States – had indicated at the end of March that it was counting on the delivery of at least 360 million doses in total in the second quarter (200 million BioNTech-Pfizer doses, 35 million Moderna, 55 million from Johnson & Johnson, as well as 70 million from AstraZeneca).

So far, member states have received some 126 million doses in total, and 100 million have been administered, von der Leyen said. In total, more than 27 million people in the EU – including some 35,100 in Luxembourg – are now fully vaccinated after receiving two injections.


Tags

Related Articles

Back to top button
Close
Close